ASX Announcements

ASX Announcements

Due to legal restrictions, only residents of Australia and New Zealand may access ASX announcements that contain information or materials relating to any capital raising.

Date Title  
22 October 2020 Remestemcel Controlled Study in Crohns & Ulcerative Colitis
13 October 2020 Phase 3 Trial in COVID-19 ARDS Surpasses 50% Enrollment
02 October 2020 Update on BLA for Graft Versus Host Disease
01 October 2020 Trading Halt
15 September 2020 MSB Wins Fierce Biotech Innovation Award for Remestemcel-L
10 September 2020 Appendix 2A
07 September 2020 Change in substantial holding
04 September 2020 DSMB Recommends Continuation of Phase 3 COVID-19 Trial
02 September 2020 Ethics Approval to Treat COVID-19 Patients in Australia
02 September 2020 Change in substantial holding
27 August 2020 MSB Annual Financial Results and Operational Progress
27 August 2020 Annual Financial Results Presentation
27 August 2020 Preliminary Final Report including Appendix 4E
26 August 2020 Mesoblast 2020 Full Year Financial Results Webcast
24 August 2020 Change in substantial holding
21 August 2020 Change in substantial holding
20 August 2020 Appendix 2A and Appendix 3G
14 August 2020 ODAC Votes in Favor of Remestemcel-L for GvHD
13 August 2020 Trading Halt
12 August 2020 Change in substantial holding - Amendment
12 August 2020 Change in substantial holding - Amendment
11 August 2020 Update on Scheduled FDA Advisory Committee Meeting
10 August 2020 Change in substantial holding
07 August 2020 Change in substantial holding
06 August 2020 Appendix 2A
06 August 2020 Proposed issue of Securities - MSB
30 July 2020 COVID-19/GVHD Update, Quarterly Report and Appendix 4C
24 July 2020 Mesoblast Expands Executive Leadership Team
21 July 2020 FDA Advisory Committee Sets Review Date for Remestemcel-L
07 July 2020 Appendix 3B, 2A with prospectus- Kentgrove Capital
06 July 2020 EAP for Remestemcel-L in Children with MIS-C due to COVID-19
30 June 2020 Appendix 2A
24 June 2020 Appendix 3G with 3Ys
16 June 2020 Appendix 2A
12 June 2020 S&P DJI Announces June 2020 Quarterly Rebalance
01 June 2020 Appendix 2A
01 June 2020 Remestemcel-L Improves Outcomes in Inflammatory Lung Disease
28 May 2020 MSB Reports Q3 Financial Results and Operational Highlights
28 May 2020 Third Quarter Results Presentation
28 May 2020 Third Quarter Financial Results on Form 6-K
27 May 2020 Change in substantial holding
25 May 2020 3 Articles on RYONCIL GvHD Trial Results Published in BBMT
19 May 2020 Change in substantial holding
18 May 2020 Cleansing Notice
15 May 2020 Appendix 2As
13 May 2020 Proposed issue of Securities - MSB
13 May 2020 MSB Completes Financing For Covid-19 ARDS Manufacturing
11 May 2020 Trading Halt
06 May 2020 First Patients Dosed in Phase 2/3 Trial for COVID-19 ARDS
30 April 2020 Phase 2/3 Trial in COVID-19 ARDS Begins Enrollment
29 April 2020 Appendix 4C - quarterly
24 April 2020 83% Survival in COVID-19 ARDS Patients with Remestemcel-L
17 April 2020 Inflammatory Lung Disease Outcomes For Presentation at ISCT
09 April 2020 US NIH Trials Network to Conduct COVID-19 Phase 2/3 Trial
06 April 2020 FDA Clears IND for Remestemcel Use in COVID-19 ARDS Patients
01 April 2020 FDA Accepts BLA for RYONCIL and Agrees to Priority Review
30 March 2020 Ischemic End Stage HF Outcomes at Virtual ACC Annual Meeting
20 March 2020 Change of Director's Interest Notice
17 March 2020 Appendix 2A
10 March 2020 Mesoblast to Evaluate Remestemcel-L in COVID-19 Lung Disease
27 February 2020 Mesoblast Provides Half Year Results and Corporate Update
27 February 2020 Half Year Financial Results Presentation
27 February 2020 Half Year Report and Accounts (including Appendix 4D)
25 February 2020 Mesoblast Half Year FY 2020 Financial Results Analyst Call
24 February 2020 Ryoncil Results in Children with Acute GvHD Presented at TCT
21 February 2020 Appendix 3G
20 February 2020 Positive Outcomes Using Remestemcel-L in Chronic GVHD
07 February 2020 Appendix 2A
03 February 2020 Mesoblast Submits Completed BLA for Ryoncil to US FDA
29 January 2020 Appendix 4C - quarterly
24 January 2020 Appendix 2A
15 January 2020 Biotech Showcase Presentation
15 January 2020 MSB Presents Commercial Plans at 2020 Biotech Showcase
02 January 2020 Appendix 2A
02 January 2020 MSB Files GvHD Clinical Efficacy and Safety Data with US FDA

Share Price :    as of Oct 14, 2020